{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:47:12Z","timestamp":1789778832508,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hebei Science and Technology Department","award":["19277747D"],"award-info":[{"award-number":["19277747D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40256-025-00722-3","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:43:47Z","timestamp":1740401027000},"page":"533-545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Administration of Evolocumab in Patients with STEMI After Emergency PCI: A Real-World Cohort Study"],"prefix":"10.1007","volume":"25","author":[{"given":"Xuefeng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiru","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongpin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"9","key":"722_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.amjcard.2019.01.037","volume":"123","author":"A Murphy","year":"2019","unstructured":"Murphy A, Hamilton G, Andrianopoulos N, et al. One-year outcomes of patients with established coronary artery disease presenting with acute coronary syndromes. Am J Cardiol. 2019;123(9):1387\u201392. https:\/\/doi.org\/10.1016\/j.amjcard.2019.01.037.","journal-title":"Am J Cardiol"},{"issue":"32","key":"722_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"41","key":"722_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"2020","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;2020(41):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"9","key":"722_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"issue":"03","key":"722_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.26599\/1671-5411.2023.09.008","volume":"38","author":"W Zengwu","year":"2023","unstructured":"Zengwu W, Jing L, Jianjun L, et al. Guidelines for blood lipid management in China. Chin J Circ. 2023;38(03):237\u201371. https:\/\/doi.org\/10.26599\/1671-5411.2023.09.008.","journal-title":"Chin J Circ"},{"issue":"32","key":"722_CR6","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","volume":"42","author":"L Da Dalt","year":"2021","unstructured":"Da Dalt L, Castiglioni L, Baragetti A, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur Heart J. 2021;42(32):3078\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/ehab431.","journal-title":"Eur Heart J"},{"issue":"12","key":"722_CR7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17425255.2020.1828343","volume":"16","author":"S Mo\u015fteoru","year":"2020","unstructured":"Mo\u015fteoru S, Gai\u0163\u0103 D, Banach M. An update on PCSK9 inhibitors-pharmacokinetics, drug interactions, and toxicity. Expert Opin Drug Metab Toxicol. 2020;16(12):1199\u2013205. https:\/\/doi.org\/10.1080\/17425255.2020.1828343.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"722_CR8","doi-asserted-by":"publisher","unstructured":"Escobar-Cervantes, C, Fernandez-Delgado, M, Roldan, C, et al. Potential low-density lipoprotein cholesterol, cardiovascular risk and costs reduction with evolocumab: a simulation in patients with a recent myocardial infarction in Spain.Eur Heart J 2023;42:42. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB724.2592.","DOI":"10.1093\/EURHEARTJ\/EHAB724.2592."},{"issue":"20","key":"722_CR9","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.010.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"722_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"106439","DOI":"10.1016\/j.phrs.2022.106439","volume":"184","author":"N Ferri","year":"2022","unstructured":"Ferri N, Ruscica M, Lupo MG, Vicenzi M, Sirtori CR, Corsini A. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacol Res. 2022;184:106439. https:\/\/doi.org\/10.1016\/j.phrs.2022.106439.","journal-title":"Pharmacol Res"},{"issue":"12","key":"722_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.rec.2017.11.010","volume":"70","author":"B Ib\u00e1nez","year":"2017","unstructured":"Ib\u00e1nez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70(12):1082. https:\/\/doi.org\/10.1016\/j.rec.2017.11.010.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"722_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129(2):234\u201343. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.007012.","journal-title":"Circulation"},{"key":"722_CR14","doi-asserted-by":"publisher","unstructured":"Atherosclerosis, Coronary heart disease working Group of Chinese Society of C and editorial Board of Chinese Journal of C. Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients. Zhonghua Xin Xue Guan Bing Za Zhi 2020;48:280\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn112148-20200121-00036.","DOI":"10.3760\/cma.j.cn112148-20200121-00036."},{"issue":"39","key":"722_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"2018","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;2018(39):119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"key":"722_CR16","doi-asserted-by":"publisher","unstructured":"Joint committee issued Chinese guideline for the management of dyslipidemia in adults. Zhonghua xin xue guan bing za zhi 2016;44(10):833\u201353. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3758.2016.10.005.","DOI":"10.3760\/cma.j.issn.0253-3758.2016.10.005"},{"issue":"1","key":"722_CR17","doi-asserted-by":"publisher","first-page":"2185252","DOI":"10.1080\/10641963.2023.2185252","volume":"45","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang C, Wan J. The correlation between T-wave abnormalities and adverse cardiovascular events and echocardiographic changes in hypertensive patients. Clin Exp Hypertens. 2023;45(1):2185252. https:\/\/doi.org\/10.1080\/10641963.2023.2185252.","journal-title":"Clin Exp Hypertens"},{"key":"722_CR18","doi-asserted-by":"publisher","unstructured":"Laboratory Medicine Society of Chinese Medical Association, Branch of Laboratory Physicians of Chinese Medical Doctor Association, Lipids and Lipoproteins Committee Chinese Society of Biochemistry and Molecular Biology, et al. China guideline for clinical lipid profile testing. Chin J Lab Med. 2022;45(10):1017\u201333. https:\/\/doi.org\/10.3760\/cma.j.cn114452-20220829-00497.","DOI":"10.3760\/cma.j.cn114452-20220829-00497."},{"issue":"2","key":"722_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report. J Clin Lipidol. 2015;9(2):129\u201369. https:\/\/doi.org\/10.1016\/j.jacl.2015.02.003.","journal-title":"J Clin Lipidol"},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","volume":"201","author":"G Savarese","year":"2015","unstructured":"Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015;201:247\u201352. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.103.","journal-title":"Int J Cardiol"},{"issue":"9","key":"722_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","volume":"146","author":"E Hagstr\u00f6m","year":"2022","unstructured":"Hagstr\u00f6m E, Steg PG, Szarek M, et al. Apolipoprotein B, Residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab. Circulation. 2022;146(9):657\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057807.","journal-title":"Circulation"},{"issue":"22","key":"722_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"1","key":"722_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12944-022-01724-9","volume":"21","author":"B Lou","year":"2022","unstructured":"Lou B, Liu H, Luo Y, et al. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction. Lipids Health Dis. 2022;21(1):105. https:\/\/doi.org\/10.1186\/s12944-022-01724-9.","journal-title":"Lipids Health Dis"},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"713007","DOI":"10.3389\/fphar.2021.713007","volume":"12","author":"W Ma","year":"2021","unstructured":"Ma W, Pan Q, Pan D, Xu T, Zhu H, Li D. Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:713007. https:\/\/doi.org\/10.3389\/fphar.2021.713007.","journal-title":"Front Pharmacol"},{"issue":"24","key":"722_CR26","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1161\/CIRCULATIONAHA.113.001258","volume":"127","author":"E Braunwald","year":"2013","unstructured":"Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation. 2013;127(24):2452\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001258.","journal-title":"Circulation"},{"issue":"4","key":"722_CR27","doi-asserted-by":"publisher","first-page":"CD011748","DOI":"10.1002\/14651858.CD011748.pub2","volume":"4","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4(4):CD011748. https:\/\/doi.org\/10.1002\/14651858.CD011748.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"722_CR28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","volume":"2","author":"MJ Koren","year":"2017","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598\u2013607. https:\/\/doi.org\/10.1001\/jamacardio.2017.0747.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"722_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/2047487315602861","volume":"23","author":"JA Tobert","year":"2016","unstructured":"Tobert JA, Newman CB. Statin tolerability:in defence of placebo-controlled trials. Eur J Prev Cardiol. 2016;23(8):891\u20136. https:\/\/doi.org\/10.1177\/2047487315602861.","journal-title":"Eur J Prev Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00722-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:08:23Z","timestamp":1751699303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00722-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00722-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"2 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was sponsored by the Scientific Research Fund from the Hebei Science and Technology Department (grant number 19277747D).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The research was executed autonomously, with the funder not participating in the study's layout, data assembly, data examination, data explanation, or report production. The authors declare that they have no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study has been approved by the medical ethics committee of Hebei General Hospital. As this study was retrospective, the need for patients' written informed consent was deemed unnecessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have contributed to the manuscript and approved the submitted version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data associated with our study has not been deposited into a publicly available repository. Data will be made available on request. The raw data information from this research is accessible from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Sun and Du developed and planned research investigation. Sun and Bai were responsible for the acquisition, analysis, and interpretation of the data. Sun drafted the manuscript. Bai, Wu, Wang, and Du critically revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}